Daiichi Sankyo Announces the Revisions of Financial Forecasts for FY2007

TOKYO, October 26, 2007 - DAIICHI SANKYO COMPANY, Limited, has made the following revisions to its financial forecasts for the first half of FY2007 (April 1, 2007-September 30, 2007) and FY2007 (April 1, 2007-March 31, 2008), which were released on July 31, 2007 with the first quarter results.

1. Revised consolidated interim forecasts of FY2007 (April 1, 2007-September 30, 2007)

(¥ million, %)

Net sales

Operating income

Ordinary income

Interim net income
Previous forecasts (A)
(announced on July 31, 2007)

416,000

75,000

80,000

44,000

Revised forecasts (B)

443,000

 93,000

100,000

60,000

Change (B ? A)

 27,000

18,000

20,000

16,000

Rate of change

6.5

 24.0

 25.0

 36.4

Actual results of comparable period
(the first half of FY2006)

485,842

78,353

88,208

66,886


 
2?Revised consolidated forecasts for FY 2007 (April 1, 2007-March 31, 2008)

(¥ million, %)

Net sales Operating income Ordinary income Net income
Previous forecasts (A)
(announced on July 31, 2007)

837,000

157,000

165,000

 92,000

Revised forecasts (B)

 876,000

160,000

171,000

100,000

Change (B ? A)

39,000

 3,000

6,000

8,000

Rate of change

4.7

 1.9

 3.6

 8.7

Actual results of comparable period(FY2006)

929,506

136,313

152,086

78,549



3. Reasons for the revisions
For the first half of FY2007, the revisions reflect mainly the continuous growth on global business, as well as the recent trends in yen exchange rate, and the partial carryover of expenses to the second half of the fiscal year, of those both net sales and interim net income forecasts are raised. Regarding the FY2007 consolidated forecasts, the revisions remains modest due to the anticipated expenses in R&D relating to the acquisition of products, while the continued increase of net sales is expected.

The performances by non-pharmaceutical businesses are partially included in these forecasts while the Daiichi Sankyo Group has been on the process of making non-pharmaceutical divisions independent to focus robustly on pharmaceutical business. The impact of non-pharmaceutical businesses on sales is 16.3 billion yen and is negligible for income.

Note: The above forecasts are based on data available at the time of this announcement. Actual results may differ significantly due to effects from various factors.

Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Takashi Shoda, President and Representative Director
(Code no.: 4568, First Section, Tokyo, Osaka and Nagoya Stock Exchanges)
Please address inquiries to Toshio Takahashi, Corporate Officer in Charge,
Corporate Communications Department
Telephone: +81-3-6225-1126
http://www.daiichisankyo.com/

Posted: October 2007


View comments

Hide
(web5)